Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes - Wikidata - wikimedia - TriplyDB

Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes

Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes

http://www.wikidata.org/entity/Q35844102

about

Higher plasma soluble Receptor for Advanced Glycation End Products (sRAGE) levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study.Soluble RAGE: therapy and biomarker in unraveling the RAGE axis in chronic disease and aging Determinants of concentrations of N(ε)-carboxymethyl-lysine and soluble receptor for advanced glycation end products and their associations with risk of pancreatic cancer Involvement of the TAGE-RAGE system in non-alcoholic steatohepatitis: Novel treatment strategies Association of serum soluble receptor for advanced glycation end-products with subclinical cerebrovascular disease: the Northern Manhattan Study (NOMAS)Evidence that serum levels of the soluble receptor for advanced glycation end products are inversely associated with pancreatic cancer risk: a prospective study.Fluorescent advanced glycation end products and their soluble receptor: the birth of new plasmatic biomarkers for risk stratification of acute coronary syndrome.Advanced glycation end products, soluble receptor for advanced glycation end products, and risk of colorectal cancer High-mobility group box-1 induces decreased brain-derived neurotrophic factor-mediated neuroprotection in the diabetic retina.sRAGE induces human monocyte survival and differentiation RAGE and soluble RAGE: potential therapeutic targets for cardiovascular diseases.RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation.Potential of the angiotensin receptor blockers (ARBs) telmisartan, irbesartan, and candesartan for inhibiting the HMGB1/RAGE axis in prevention and acute treatment of stroke.Receptor for advanced glycation end products: its role in Alzheimer's disease and other neurological diseases.Receptor for AGE (RAGE) and its ligands-cast into leading roles in diabetes and the inflammatory response AGE and their receptor RAGE in systemic autoimmune diseases: an inflammation propagating factor contributing to accelerated atherosclerosis.Role of Advanced Glycation End Products and Its Receptors in the Pathogenesis of Cigarette Smoke-Induced Cardiovascular Disease.Effect of diet-derived advanced glycation end products on inflammation.Effect of Nɛ-carboxymethyllysine on oxidative stress and the glutathione system in beta cells.Involvement of TAGE-RAGE System in the Pathogenesis of Diabetic Retinopathy.Is Elevated Levels of Serum Soluble Receptor for Advanced Glycation End Products Harmful in Cigarette Smokers?What does Cigarette Smoking do to the Circulating Level of Soluble Receptor for Advanced Glycation End Products?Effects of glycation of the model food allergen ovalbumin on antigen uptake and presentation by human dendritic cells.Effects of ferric citrate supplementation on advanced glycation end products in a rat model of streptozotocin/nicotinamide-induced diabetes.Serum soluble receptor for advanced glycation end products (sRAGE) is independently associated with cigarette smoking in non-diabetic healthy subjects.The Role of Advanced Glycation End Products in Diabetic Vascular Complications.Pregnancy-associated plasma protein A (PAPP-A) and soluble receptor for advanced glycation end products (sRAGE) – intra- and inter-individual variability in chronic hemodialysis patients Anti-inflammatory effect of biological treatment in patients with inflammatory bowel diseases: Calprotectin and IL-6 changes do not correspond to sRAGE changes Role of the Soluble Receptor for Advanced Glycation End Products (sRAGE) as a Prognostic Factor for Mortality in Hemodialysis and Peritoneal Dialysis Patients

P2860

Q34024272-C974D3B2-E098-4F37-B030-A15B5FC4052C Q34094369-C05EA825-A7F8-4CF5-8F17-55826CD90B69 Q34426525-0E7ACBDE-2BCB-4529-B986-6D5DFE27EAB2 Q34728267-BDABD472-8E6D-407D-AE8E-34D76ACBA230 Q34949171-0852CA47-536D-47D6-BBA0-020918124ED1 Q34987953-C73A0BD3-CEC3-4B68-AA10-38F9EE57BA34 Q34994616-48826285-CB70-4CA8-9800-6760F9D591C7 Q35093747-9A1CEC27-9FBD-4274-A1A5-AA6EE39C33D4 Q36900033-06FE16B2-FEDF-42CA-A9EE-08987FB722D0 Q36900801-FB7290F8-3743-4540-8DCE-A347E12FD796 Q36969021-721E5FDB-B181-46F9-82BA-61B9E8E4958B Q37152947-A2A6AA90-28E9-4FBE-87C1-FE4B3846F98E Q37225236-40BF5B0A-B472-45D6-A2EF-B32DE494B58F Q37259863-C15316AB-06F8-4A48-9CAD-7D3A75BF187A Q37384331-0FE1E715-E7FA-4DC6-940F-63EBC83A6535 Q37610425-AFEEFBC3-C49F-4DAC-8ED0-4F531DAB49E4 Q38523267-99435507-CE08-4A1C-8B75-121D27601C7F Q38588208-B8E9DB40-487B-4087-8D19-511B464C2DAE Q41681406-842C0B67-829A-408A-B970-95AD31F481E1 Q41789363-427BC647-32E3-4F59-AF9D-BA8A375BAFA7 Q41975172-216A2041-CAE5-46E9-B76D-E21DEF58AA23 Q42781806-4998288E-ED03-4875-B73E-BE3932C0EBB0 Q43239563-0F63FEB1-A7A6-4778-87C5-E5D5E95AB9D5 Q51318083-425A8883-D9B3-43E3-A7B2-D644FD53D6AC Q51342915-CAAB8AA7-E2F6-47F8-9A4E-99C512F27C7F Q55416114-BA89EB86-98F4-4B92-8A8B-68E018A18A28 Q57825168-3633BC00-C60D-489B-BFF2-F3DBA720D902 Q57825203-F5970D86-7CA5-40F1-B3C6-1D7D608790C5 Q58564998-5870E467-EEB5-47D0-A858-3AC733C923D2

P2860

Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes

http://www.wikidata.org/entity/Q35844102

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

2007年學術文章

@zh

2007年學術文章

@zh-hant

name

Serum levels of sRAGE, the sol ...... patients with type 2 diabetes

@ast

Serum levels of sRAGE, the sol ...... patients with type 2 diabetes

@en

type

label

Serum levels of sRAGE, the sol ...... patients with type 2 diabetes

@ast

Serum levels of sRAGE, the sol ...... patients with type 2 diabetes

@en

prefLabel

Serum levels of sRAGE, the sol ...... patients with type 2 diabetes

@ast

Serum levels of sRAGE, the sol ...... patients with type 2 diabetes

@en

P1433

Q35844102-DE262932-F145-4AA1-8C76-C14C53961B30

P1476

Q35844102-9B4D940A-9D15-4A92-B7D2-B3B0AA1C921F

P2093

Q35844102-025698CA-7235-417B-ABC0-FD9A9CE4E342

Q35844102-30979231-80A0-46B7-894B-6753EC19009E

Q35844102-32D9D7E3-DE3A-44C0-88A8-0E0FECD4283F

Q35844102-4B94FE75-EB3E-48D1-8809-FFECAB06446E

Q35844102-86ECDE70-D809-44BB-9C2D-5E50B78F61C0

Q35844102-985A28E1-7F52-4DEB-967E-CB3469027A63

Q35844102-A20E577B-83E5-4E3D-8EAD-4DE20086C97F

P2860

Q35844102-01BD93E4-9CB7-424B-BA2A-C997AA7B2D48

Q35844102-03FD0545-7345-456F-AE1F-D6F975B3EE78

Q35844102-07E29190-7054-4597-84A4-6134DAF90A10

Q35844102-0C914AF0-FB60-443D-89EA-64D5DC1E5F18

Q35844102-0FB1BE5F-208E-428D-B3B6-4A259BEF3B59

Q35844102-11ABF451-8A01-4D30-9A22-320CD6B237A8

Q35844102-236B0464-0E24-42EB-AE46-A5A2D9FB20A1

Q35844102-309CBC72-CBD6-47F0-9BEF-9D04BBAB1729

Q35844102-33533FC7-2486-40DA-B87C-8FBFBCF569B2

Q35844102-38707C23-2404-40F2-AF35-EAF6309584B3

P2888

Q35844102-D229162A-2C04-427A-B771-A8CBF109AC54

P304

Q35844102-ACE4BDA5-E024-4394-8844-7D5BF3F7F587

P31

Q35844102-2C5FC618-C5CC-4EBB-8CDC-2B1C16DDF3E3

P356

Q35844102-B09758A5-C9F0-47E7-A17E-1ECB29F2CFF1

P407

Q35844102-06760AE3-2B2D-4294-976B-75FDD38C85D1

P433

Q35844102-17E73E4D-B949-4E1F-AC37-515CA4695D4C

P478

Q35844102-14D8ED50-6DED-447F-A068-A842D93BA4D3

P577

Q35844102-57C6287A-7BD9-47EF-ABFC-B7EA8027E24B

P6179

Q35844102-4D54BA7B-D069-4B6F-A937-4BFC9D05A0DB

P698

Q35844102-EC6B40E8-720B-48E4-BF64-10ACCF43C1A7

P921

Q35844102-0AD92F01-B9C0-42E7-9D7C-ED4983BF5FA9

Q35844102-A4A96019-8DF0-451B-A1D8-2FE93D3A1A1D

P932

Q35844102-2F8950A7-A49C-4CD5-A414-582B5F60C7FA

P356

2006-00090.NAKAMURA

P1433

Molecular Medicine

P1476

Serum levels of sRAGE, the sol ...... patients with type 2 diabetes

@en

P2093

Hisashi Adachi

http://www.w3.org/2001/XMLSchema#string

Kazuo Nakamura

http://www.w3.org/2001/XMLSchema#string

Sho-ichi Yamagishi

http://www.w3.org/2001/XMLSchema#string

Takafumi Yoshida

http://www.w3.org/2001/XMLSchema#string

Takanori Matsui

http://www.w3.org/2001/XMLSchema#string

Tsutomu Imaizumi

http://www.w3.org/2001/XMLSchema#string

Yayoi Kurita-Nakamura

http://www.w3.org/2001/XMLSchema#string

P2860

Formation of pentosidine during nonenzymatic browning of proteins by glucose. Identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo

Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus

Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis.

Atherosclerosis and diabetes: the RAGE connection.

Advanced protein glycosylation in diabetes and aging.

Mechanism of formation of the Maillard protein cross-link pentosidine. Glucose, fructose, and ascorbate as pentosidine precursors.

Oral adsorbent AST-120 decreases serum levels of AGEs in patients with chronic renal failure.

Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy.

Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease.

Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target.

P2888

2006-00090.nakamura

P304

185-189

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2119/2006-00090.NAKAMURA

http://www.w3.org/2001/XMLSchema#string

P407

P433

3-4

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P577

2007-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1068964974

http://www.w3.org/2001/XMLSchema#string

P698

17592553

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

1892766

http://www.w3.org/2001/XMLSchema#string